This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Innovations by Stanley Hefta in Hepatotoxicity Prediction
Introduction
Stanley Hefta is an accomplished inventor based in Pennington, NJ (US). He has made significant contributions to the field of biomedical research, particularly in the identification of biomarkers for liver toxicity. His work aims to enhance the safety and efficacy of therapeutic agents by predicting potential hepatotoxic effects.
Latest Patents
Stanley Hefta holds a patent related to the identification of biomarkers for liver toxicity. The patent encompasses biomarker polypeptides, polynucleotides, and antibodies that are instrumental in predicting both in vitro and in vivo hepatotoxicity of various drugs and compounds. The invention also includes screens, kits, microarrays, and cell culture systems that utilize these biomolecules. The methods and reagents developed through this patent are designed to identify test substances that may cause hepatic injury, thereby preventing serious medical complications such as liver failure.
Career Highlights
Stanley Hefta is associated with Bristol-Myers Squibb Company, where he applies his expertise in drug safety and biomarker research. His innovative work has the potential to significantly impact the pharmaceutical industry by improving the pre-clinical and clinical testing processes.
Collaborations
He has collaborated with notable colleagues, including Stephen M Storm and Stephen K Durham, to advance research in the field of hepatotoxicity and drug safety.
Conclusion
Stanley Hefta's contributions to the identification of biomarkers for liver toxicity represent a significant advancement in the field of biomedical research. His innovative approaches have the potential to enhance drug safety and efficacy, ultimately benefiting patient health.